Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-05T05:09:00.638Z Has data issue: false hasContentIssue false

Chapter 14 - Melanoma

from Part II - Oncologic applications

Published online by Cambridge University Press:  05 September 2012

Victor H. Gerbaudo
Affiliation:
Brigham and Women's Hospital, Harvard Medical School
Get access

Summary

Introduction

Malignant melanoma, a neoplasm of melanocytes, has a lifetime risk of 1 per 75 people in North America, and accounts for only 5% of skin cancers, but is responsible for three times as many deaths as non-melanoma skin cancers (1). Both the incidence rate and mortality from the disease have increased significantly since the 1970s, though the former may be partly attributed to increased awareness and screening (2, 3). Melanoma is primarily a disease of white people; rates are up to 20 times higher in whites than in African Americans. Major risk factors apart from race include family history of melanoma, atypical or numerous nevi, sun sensitivity, a history of excessive UV exposure, immunosuppressed states, and occupational exposure to carcinogens (1).

Staging

Melanoma is staged using the widely accepted American Joint Committee on Cancer's (AJCC) TNM staging system, which was most recently updated in 2009 (4). This system defines stage by features of the primary tumor (T), the presence or absence of tumor spread to regional lymph nodes (N) and the presence or absence of metastasis to distant sites (M) (Table 14.1). The TNM classifications are then organized into anatomic stage groupings, which dictate prognosis, treatment options and are predictive of other expected features of the disease in a given patient (Table 14.2).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Cancer Society 2009 http://www.cancer.org/downloads/STT/500809web.pdf
Hall, HIMiller, DRRogers, JDUpdate on the incidence and mortality from melanoma in the United StatesJ Am Acad Dermatol 1999 40 35CrossRefGoogle ScholarPubMed
Welch, HGWoloshin, SSchwartz, LM.Skin biopsy rates and incidence of melanoma: population based ecological studyBr Med J 2005 331CrossRefGoogle ScholarPubMed
Balch, CMGershenwald, JESoong, SJFinal version of 2009 AJCC melanoma staging and classificationJ Clin Oncol 2009 27 6199CrossRefGoogle ScholarPubMed
Essner, R.Surgical treatment of malignant melanomaSurg Clin North Am 2003 83 109CrossRefGoogle ScholarPubMed
Fecher, LAFlaherty, KT.Where are we with adjuvant therapy of stage III and IV melanoma in 2009?J Natl Compr Canc Netw 2009 7 295CrossRefGoogle ScholarPubMed
Atkins, MBLotze, MTDutcher, JPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol 1999 17 2105CrossRefGoogle ScholarPubMed
Kirkwood, JMStrawderman, MHErnstoff, MSInterferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol 1996 14 7CrossRefGoogle ScholarPubMed
Dhomen, NMarais, R.BRAF signaling and targeted therapies in melanomaHematol Oncol Clin North Am 2009 23 529CrossRefGoogle ScholarPubMed
Gritters, LSFrancis, IRZasadny, KRInitial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanomaJ Nucl Med 1993 34 1420Google ScholarPubMed
Friedman, KPWahl, RL.Clinical use of positron emission tomography in the management of cutaneous melanomaSemin Nucl Med 2004 34 242CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×